Clinical Trials Browser

MLN 8237 × Thoracic × 90 days × Clear all

NCT06095505 2026-06-05

ALISCA-Lung1

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms